We report on a 44-year-old male with primary cardiac angiosarcoma who died 11 months after onset of nonspecific symptoms (thoracic pain and general fatigue) of intracerebral metastases. A right atrial tumor mass and a pericardial effusion could be demonstrated by transthoracic and transesophageal echocardiography. Cardiac angiography showed a right atrial hemangioma, fed by the right coronary artery.
Cardiac catheterization (9/28/89): Normal pressures were recorded for right atrium, right ventricular inflow tract, pulmonary artery and pulmonary capillary wedge pressure, left ventricle and ascending aorta. Ventriculography showed thickening of the pericardium in the right atrium of some 2cm with possible pericardial effusion. Normal diameters were found for left ventricle and normal contractility; ejection fraction was 76%. The right coronary artery fed via an atrial branch a vascularized mass within the right atrium. Coronaries were otherwise normal. (Fig. 1) The presumed diagnosis was right atrial hemangioma/hemangiosarcoma causing cardiac tamponade by massive hemorrhagic pericardial effusion. A surgical resection of the tumor was planned but refused by the patient. Because the pericardial fluid had failed to reveal any malignant cells, the patient was discharged without specific therapy and regularly seen as an outpatient. obtain histologic tumor material was done and the diagnosis of a primary angiosarcoma of the heart was confirmed by this method. The right atrial tumor was felt to be inoperable due to its rapid growth and size and polychemotherapy on the CWS protocol was begun. (Duration 4/4/90 to 5/26/90:8 days of carboplastin 500mg/m2, vincristine 1.5mg/m2, followed by 8 days of ifosfamide 3g/m2, Actinomycin D 1.5mg/m2, vincristine 1.5mg/ m2, and finally 8 days of ifosfamide 3g/m2, VP-16 200mg/m2 and vincristine 1.5mg/m2).
The patient finished one cycle of treatment and regression of primary tumor mass as well as of intrapulmonary metastases could be demonstrated on CXR and thoracic CT. Clinical features of cardiac angiosarcomas were well described by Glancy et al (1968) and Janigan et al (1986) . Recently Herrman et al (1992) published a review of another 6 cases. We add a review of another 15 cases to the former description of 41 by Glancy et al, 46 cases by Janigan et al, and 6 cases by Herrman et al, leading to a total of 108 cases of primary cardiac angiosarcoma (including the one case presented here, see Tables I-VII) , covered in this review.
Age range is 10-80 years, mean 39.6 years. Men appear to be affected more often than women, accounting for 67.6% of all 108 cases reviewed. Symptoms were uniformly determined by tumor location. The right atrium was the primary tumor site in 71.4% of cases, either as the only tumor site (55.6%) or in combination with the right ventricle (6.5%), in combination with the pericardium In the review by Glancy et al1) the number of autopsies is not stated, but the authors report in 40 patients with prim. angiosarcoma of the heart the following localizations of metastases: lungs: 24, liver: 11, lymph nodes: 10, bone: 7, adrenal glands: 5, CNS: 2, spleen: 2, peritoneum: 2, kidneys: 1, pancreas: 1, thyroid gland: 1, muscle: 1, prostate: 1, ovaries: 1. Table IV . Tumor Location in Primary Angiosarcoma of the Heart *In 1 patient it could not be determined whether the primary tumor site was the pericardium (P) or the lungs.
(6.5%), in combination with the left atrium (0.9%), or in combination with the right ventricle and pericardium (1.9%). The right atrium being affected by tumor mass in more than 70% of cases, it is not surprising that the presenting symptoms are often those of right atrial inflow obstruction with distended jugular veins, Jpn. Heart J. September 1993 *Surgical resection was not performed in another 8 of 32 patients due to extensive tumor size seen intraoperatively. **32 patients in whom primary angiosarcoma of the heart was diagnosed intra vitam and appropriate treatment could be started.
other supraventricular rhythm disorders occurred in 8.4% of all patients, nonspecific ST-T changes were present in 36.1%. Only one patient showed AV conduction disturbances (0.9%). Imaging techniques to demonstrate intracardiac masses include echocardiography, cardiac catheterization, CT-scan, MR, and to some extent conventional chest-roentgenography.
In 78.7% of all patients cardiomegaly could be shown by chest X-ray, in 15.7% a prominent right atrial silhouette was detected on the chest X-ray film. The typical echocardiographic finding in primary cardiac malignancy is a right atrial tumor mass [11 of 27 patients (40.7%), in whom echocardiographic results were stated], possibly associated with pericardial effusion. In rare instances only enlargement of a single cardiac chamber (14.8%), or thickening of cardiac walls (7.4%) may be detected. Cardiac catheterization usually reveals a filling defect at the tumor site (66.7%). Endomyocardial biopsy was performed in 4 cases, two of which were falsely negative. In all but one case with hemorrhagic pericardial effusion, microscopic and histologic examination of the pericardial fluid were falsely negative. From these results it is obvious that accurate diagnosis of intracardiac malignancy can only be obtained with open biopsy of either the primary tumor mass or secondary tumor deposits. Unfortunately endomyocardial biopsy, pericardial or pleural biopsy as well as histologic examination of the pericardial effusion often found in primary cardiac malignancy frequently are falsely negative and may delay appropriate treatment. Even though tumor location and extent can be determined by echocardiography, CT and MR, no definite statement on tumor type can be made at present by imaging techniques alone (as long as no metastases have occurred). Echocardiographic evidence of a right atrial mass, not consistent with thrombus material, in association with hemorrhagic pericardial effusion should raise high suspicion towards primary cardiac malignancy and warrants further investigation.
Metastases in primary angiosarcoma of the heart are common and were present in 88.4% of the 43 patients in whom complete autopsy was performed. The most common metastatic sites of cardiac angiosarcoma are the lungs (51.2%), followed by liver (37.2%), CNS (30.2%), bone (20.9%) and lymph nodes (16.3%). Other metastatic sites include ovaries, pancreas, peritoneum, spleen, kidneys, and skin. Pleura and pericardium are not regarded as metastatic sites in this overview but rather as being involved by direct tumor invasion. Mean survival time in Glancy's overview was 5.9 months in the 33 patients in whom duration of symptoms could be determined. In Janigan's review, mean survival time was differentiated: for patients who did not undergo surgery: 4.2 months; 8 of 23 patients who underwent surgery died postoperatively, of the surviving 15, the mean survival time was 10.6 months. In the present review mean survival time from onset of symptoms was 11.9 months, with 2 patients being alive at the time of description.11),12) Of the patients with the longest reported survival time (39 and 22 months, respectively) 12),13) one was treated by surgery, radiation and chemotherapy, the other one (22 months survival time) refused further treatment after resection was determined to be impossible. It is noteworthy that both patients with long survival times12),13) had no metastases clinically, although no autopsy was performed in either case. The patient with 39 months survival time was still alive at the time of description.12) From these results it seems that survival time in primary angiosarcoma of the heart has improved in recent years, which may partly be due to early diagnosis by echocardiogram/cardiac catheterization in patients with nonspecific cardiac symptoms. 
CONCLUSION

